Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspire Medical Systems (NYSE:INSP) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Inspire Medical Systems's Enterprise Value for the quarter that ended in Mar. 2026 was $1,231.3 Mil.
Inspire Medical Systems's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspire Medical Systems EV-to-EBIT Related Terms
Inspire Medical Systems EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Inspire Medical Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspire Medical Systems EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Inspire Medical Systems's EV-to-EBIT falls into.
Inspire Medical Systems's current Enterprise Value is $1,253.2 Mil.
Inspire Medical Systems's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspire Medical Systems (INSP) has a EV-to-EBIT of 20.69 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inspire Medical Systems and its competitors. According to the industry distribution chart, Inspire Medical Systems ranks #244 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 51.9%.
Is Inspire Medical Systems' EV-to-EBIT too high?
Inspire Medical Systems' current EV-to-EBIT is 20.69. The Medical Devices & Instruments industry median EV-to-EBIT is 18.92. Inspire Medical Systems' value of 20.69 is 9.4% above this industry median. Based on the distribution chart, Inspire Medical Systems ranks #244 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Inspire Medical Systems has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inspire Medical Systems' EV-to-EBIT compare to AHCO and IART?
According to the Medical Devices & Instruments industry distribution chart, Inspire Medical Systems ranks #244 out of 470 companies for EV-to-EBIT. This places Inspire Medical Systems in the lower half of its industry. The industry median EV-to-EBIT is 18.92. Inspire Medical Systems' value of 20.69 is 9.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.92, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspire Medical Systems's current EV-to-EBIT of 20.69 is 9.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Inspire Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire Medical Systems's current EV-to-EBIT is 20.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Inspire Medical Systems (INSP) is currently considered Possible Value Trap. The stock's GF Value™ is $215.17, compared to a current price of $52.32 — trading 75.7% below its estimated fair value. The current EV-to-EBIT is 20.69 and 9.4% above the Medical Devices & Instruments industry median of 18.92. Inspire Medical Systems' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Inspire Medical Systems (INSP), the current EV-to-EBIT is 20.69 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspire Medical Systems (INSP) Overvalued in 2026?
Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued.
The current stock price of $52.32 is trading 75.7% below its estimated GF Value™ of $215.17.
GuruFocus considers Inspire Medical Systems to be Possible Value Trap.
Key valuation signals for INSP:
EV-to-EBIT: 20.69
GF Value™: $215.17 vs. price of $52.32 (75.7% below fair value)
Industry Position: 9.4% above the Medical Devices & Instruments median (#244 of 470)
No single metric tells the full story. See the INSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
54GF Score
Get the complete analysis for INSP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INSP has been successfully added to your 
